Program in Translational Therapeutics
To promote and accelerate early phase clinical development of novel translational therapeutics by building matrix partnerships between interdisciplinary and inter-institutional laboratory and clinical investigators.
- To extend and expand the critical mass of expertise and leadership in Translational Therapeutics that is an identifiable resource for trainees and both intra- and extra-mural collaborators.
- To facilitate translational therapeutics with engineered cells.
- To promote translational science using engineered RNA and targeted nanomedicines.
- To address the emerging disparities that restrict access to novel cell and gene therapies.
Carl June, MD – Professor
Department of Pathology and Laboratory Medicine
Director of Translational Research of the Abramson Cancer Center
Drew Weissman, MD, PhD
Department of Medicine
Co-Director, Penn Center for AIDS Research, Immunology Core
General inquiries can be sent to email@example.com